Clinical Trial Update: Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update on anti-hormonal therapy with ribociclib in HR-positive, HER2-negative metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Cancer Metastasis

Drugs mentioned

• Ribociclib (ribociclib)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Breast Cancer Metastatic | Phase 2 | Status: COMPLETED